Maruishi Pharmaceutical has filed a new drug application in Japan for an injectable agent containing difelikefalin, MR13A9, for the treatment of pruritus in hemodialysis patients, the company and its codeveloper Kissei Pharmaceutical said on September 28. Difelikefalin, a selective kappa…
To read the full story
Related Article
- Kissei/Maruishi’s Pruritus Drug Hits Mark in Japan PIII Study
January 11, 2022
- Kissei, Maruishi Join Hands on Opioid Receptor Agonist
March 14, 2017
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





